T. Orchard, H. Holt, and L. Bradbury, The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.5, issue.2
DOI : 10.1097/00054725-199905000-00004

S. Arvikar and M. Fisher, Inflammatory bowel disease associated arthropathy, Current Reviews in Musculoskeletal Medicine, vol.68, issue.18, pp.123-154, 2011.
DOI : 10.1136/ard.2008.092833

C. Stolwijk, M. Pierik, and R. Landewé, Prevalence of Self-Reported Spondyloarthritis Features in a Cohort of Patients with Inflammatory Bowel Disease, Canadian Journal of Gastroenterology, vol.27, issue.4, pp.199-205, 2013.
DOI : 10.1155/2013/139702

I. Yacoub, Y. Amine, B. Laatiris, and A. , Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis, Rheumatology International, vol.59, issue.6, pp.357-360, 2012.
DOI : 10.1002/art.23704

K. Subramaniam, K. Tymms, and B. Shadbolt, Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors, Internal Medicine Journal, vol.76, issue.Suppl, pp.1154-1160, 2015.
DOI : 10.1016/j.jbspin.2008.12.008

F. Gomollon, A. Dignass, and V. Annese, 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn???s Disease 2016: Part 1: Diagnosis and Medical Management, Journal of Crohn's and Colitis, vol.11, issue.1, pp.3-25, 2017.
DOI : 10.1093/ecco-jcc/jjw168

F. Magro, P. Gionchetti, and R. Eliakim, Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders, Journal of Crohn's and Colitis, vol.124, issue.76, pp.649-670, 2017.
DOI : 10.1016/S0016-5085(03)00171-9

L. Praet, . Van, L. Jans, and P. Carron, Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort, Annals of the Rheumatic Diseases, vol.43, issue.6, pp.1186-1195, 2014.
DOI : 10.1093/rheumatology/keh008

L. Peyrin-biroulet, V. Billioud, D. Haens, and G. , Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process, The American Journal of Gastroenterology, vol.12, issue.1, pp.1770-1776, 2012.
DOI : 10.1053/j.gastro.2005.12.019

H. Cypers, G. Varkas, and S. Beeckman, Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis, Annals of the Rheumatic Diseases, vol.60, issue.7, pp.1357-1362, 2016.
DOI : 10.1002/art.24349

L. Peyrin-biroulet, W. Sandborn, and B. Sands, Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, The American Journal of Gastroenterology, vol.107, issue.9, pp.1324-1362, 2015.
DOI : 10.1038/ajg.2012.117

URL : https://hal.archives-ouvertes.fr/hal-01191653

F. Baert, L. Moortgat, G. Assche, and . Van, Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease, Gastroenterology, vol.138, issue.2, pp.463-471, 2010.
DOI : 10.1053/j.gastro.2009.09.056

J. Colombel, P. Rutgeerts, and W. Sandborn, Adalimumab Induces Deep Remission in Patients With Crohn's Disease, Clinical Gastroenterology and Hepatology, vol.12, issue.3, pp.414-436, 2014.
DOI : 10.1016/j.cgh.2013.06.019

J. Colombel, P. Rutgeerts, and W. Reinisch, Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis, Gastroenterology, vol.141, issue.4, pp.1194-1201, 2011.
DOI : 10.1053/j.gastro.2011.06.054

D. Laharie, J. Filippi, and X. Roblin, Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience, Alimentary Pharmacology & Therapeutics, vol.120, issue.1, pp.998-1004, 2013.
DOI : 10.1053/gast.2001.20912

URL : https://hal.archives-ouvertes.fr/hal-01703099

J. Miyoshi, K. Matsuoka, and N. Inoue, Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients, Journal of Crohn's and Colitis, vol.317, issue.12, pp.609-614, 2013.
DOI : 10.1056/NEJM198712243172603

S. Ardizzone, A. Cassinotti, and P. Duca, Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.9, issue.6, pp.483-489, 2011.
DOI : 10.1016/j.cgh.2010.12.028

P. Allen, P. Olivera, and P. Emery, Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis, Alimentary Pharmacology & Therapeutics, vol.14, issue.Suppl. 3, pp.1058-1072, 2017.
DOI : 10.1136/gutjnl-2016-312648

L. Vuitton, L. Peyrin-biroulet, and J. Colombel, Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus, Alimentary Pharmacology & Therapeutics, vol.12, issue.6, pp.801-813, 2017.
DOI : 10.1016/j.cgh.2013.07.022

L. Vuitton, P. Marteau, and W. Sandborn, IOIBD technical review on endoscopic indices for Crohn's disease clinical trials, Gut, vol.59, issue.(Suppl), pp.1447-55, 2016.
DOI : 10.1136/gut.2009.194159

J. Colombel, R. Panaccione, and P. Bossuyt, Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm, Gastroenterology, vol.152, issue.5, p.155, 2017.
DOI : 10.1016/S0016-5085(17)30842-9

M. Osterman, F. Aberra, and R. Cross, Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.12, issue.11, pp.1887-1893, 2014.
DOI : 10.1016/j.cgh.2014.03.035

L. Schipper, M. Vermeer, and H. Kuper, A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry, Annals of the Rheumatic Diseases, vol.71, issue.6, pp.845-50, 2012.
DOI : 10.1136/annrheumdis-2011-200274

J. Pope, B. Haraoui, and E. Rampakakis, Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real-World Cluster-Randomized Adalimumab Trial, Arthritis Care & Research, vol.63, issue.9, pp.1401-1410, 2013.
DOI : 10.1002/acr.20643

J. Cheng and . Wei-chung, Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs, Drugs, vol.74, issue.10, pp.1091-1097, 2014.

D. Heijde, R. S. Van, and R. Landewé, 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Annals of the Rheumatic Diseases, vol.68, issue.(4), pp.978-991, 2017.
DOI : 10.1136/annrheumdis-2016-210770

D. Poddubnyy, M. Protopopov, and H. Haibel, High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort, Annals of the Rheumatic Diseases, vol.67, issue.10, pp.2114-2118, 2016.
DOI : 10.1002/art.23260

X. Baraliakos and J. Braun, Anti-TNF-?? therapy with infliximab in spondyloarthritides, Expert Review of Clinical Immunology, vol.62, issue.1, pp.9-19, 2010.
DOI : 10.1136/ard.2003.009589

J. Smolen, J. Braun, and M. Dougados, Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force, Annals of the Rheumatic Diseases, vol.66, issue.suppl 2, pp.6-16, 2014.
DOI : 10.1136/ard.2007.071092

D. Baeten, J. Sieper, and J. Braun, Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, New England Journal of Medicine, vol.373, issue.26, pp.2534-2548, 2015.
DOI : 10.1056/NEJMoa1505066

A. Ford, S. V. Kane, and K. Khan, Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, vol.86, issue.4, pp.617-646, 2011.
DOI : 10.1056/NEJMoa0904492

W. Lim, Y. Wang, and J. Macdonald, Aminosalicylates for induction of remission or response in Crohn's disease, Cochrane Database Syst Rev, vol.7, p.8870, 2016.

A. Ford, J. Achkar, and K. Khan, Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, vol.93, issue.4, pp.601-616, 2011.
DOI : 10.1016/0016-5085(87)90253-8

Y. Wang, C. Parker, and T. Bhanji, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database of Systematic Reviews, vol.3, issue.2, p.543, 2016.
DOI : 10.1002/14651858.CD000543.pub2

Y. Wang, C. Parker, and B. Feagan, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database of Systematic Reviews, vol.3, issue.2, p.544, 2016.
DOI : 10.1002/14651858.CD000544.pub2

M. Harbord, R. Eliakim, and D. Bettenworth, Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management, Journal of Crohn's and Colitis, vol.111, issue.7, pp.1-24
DOI : 10.1038/ajg.2016.54

J. Braun, J. Zochling, and X. Baraliakos, Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial, Annals of the Rheumatic Diseases, vol.65, issue.9, pp.1147-53, 2006.
DOI : 10.1136/ard.2006.052878

J. Chen, S. Lin, and C. Liu, Sulfasalazine for ankylosing spondylitis, Cochrane Database Syst Rev, vol.11, p.4800, 2014.

?. Ward, M. Deodhar, A. Akl, and E. , American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network, 2015.

. American-college and . Rheumatology, Spondylitis Association of America/Spondyloarthrithis Research and treatment network recommendations for the treatment of r-axSpA and nr-axSpA

C. Mallinson, P. Thorne, and D. Rahman, 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations, J Rheumatol, vol.4242, pp.665-681, 2015.

R. Summers, D. Switz, and J. Sessions, National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, vol.77, pp.847-69, 1979.

H. Malchow, K. Ewe, and J. Brandes, European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment, Gastroenterology, vol.86, pp.249-66, 1984.

W. Sandborn, B. Bosworth, and S. Zakko, Budesonide Foam Induces Remission in Downloaded by, p.36, 2017.

D. Turner, C. Walsh, and A. Steinhart, Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression, Clinical Gastroenterology and Hepatology, vol.5, issue.1, pp.103-113, 2007.
DOI : 10.1016/j.cgh.2006.09.033

H. Haibel, C. Fendler, and J. Listing, Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial, Annals of the Rheumatic Diseases, vol.70, issue.Suppl 2
DOI : 10.1136/ard.2011.151043

?. Sieper, J. Poddubnyy, and D. , New evidence on the management of spondyloarthritis, Nature Reviews Rheumatology, vol.74, issue.5, pp.282-95, 2016.
DOI : 10.1136/annrheumdis-2015-eular.2254

N. Chande, C. Townsend, and C. Parker, Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease, Cochrane Database Syst Rev, vol.10, p.545, 2016.

S. Ardizzone, G. Maconi, and A. Russo, Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, vol.55, issue.1, pp.47-53, 2006.
DOI : 10.1136/gut.2005.068809

L. Chebli, L. Chaves, M. Pimentel, and F. , Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis???, Inflammatory Bowel Diseases, vol.15, issue.4, pp.613-622, 2010.
DOI : 10.1002/ibd.20875

N. Chande, P. Patton, and D. Tsoulis, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database of Systematic Reviews, vol.122, issue.1, p.67, 2015.
DOI : 10.1002/14651858.CD000067.pub2

A. Timmer, P. Patton, and N. Chande, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev Downloaded by, p.36, 2017.

J. Colombel, W. Sandborn, and W. Reinisch, Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-95, 2010.
DOI : 10.1056/NEJMoa0904492

R. Panaccione, S. Ghosh, and S. Middleton, Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis, Gastroenterology, vol.146, issue.2, pp.392-400, 2014.
DOI : 10.1053/j.gastro.2013.10.052

B. Feagan, J. Rochon, and R. Fedorak, Methotrexate for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.332, issue.5, pp.292-299, 1995.
DOI : 10.1056/NEJM199502023320503

J. Mcdonald, Y. Wang, and D. Tsoulis, Methotrexate for induction of remission in refractory Crohn's disease, Cochrane Database Syst Rev, vol.8, p.3459, 2014.

B. Feagan, J. Mcdonald, and R. Panaccione, Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease, Gastroenterology, vol.146, issue.3, pp.681-688, 2014.
DOI : 10.1053/j.gastro.2013.11.024

F. Carbonnel, J. Colombel, and J. Filippi, Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative??Colitis, Gastroenterology, vol.150, issue.2, pp.380-388, 2016.
DOI : 10.1053/j.gastro.2015.10.050

URL : https://hal.archives-ouvertes.fr/hal-01303796

Y. Wang, J. Macdonald, and B. Vandermeer, Methotrexate for maintenance of remission in ulcerative colitis, Cochrane Database of Systematic Reviews, vol.102, issue.3, p.7560, 2015.
DOI : 10.1002/14651858.CD007560.pub2

H. Haibel, H. Brandt, and I. Song, No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial, Annals of the Rheumatic Diseases, vol.66, issue.3, pp.419-440, 2007.
DOI : 10.1136/ard.2006.054098

Z. Ash, C. Gaujoux-viala, and L. Gossec, A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis Downloaded by, p.36, 2017.

D. Vries, L. Wildenberg, M. , D. Jonge, and W. , The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohn's Colitis, 2017.

D. Heijde, A. Deodhar, and J. Wei, Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

A. Armuzzi, C. Felice, and E. Lubrano, Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts, Digestive and Liver Disease, vol.49, issue.12, pp.1590-865830934, 2017.
DOI : 10.1016/j.dld.2017.06.004

W. Moon and E. Loftus, Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in??inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.287, issue.Pt 4, pp.863-883, 2016.
DOI : 10.1074/jbc.M112.363010

F. Macaluso, R. S. Maida, and M. , Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience, Scandinavian Journal of Gastroenterology, vol.8, p.1
DOI : 10.1136/gutjnl-2013-306711

S. Murphy, L. Wang, and L. Anderson, Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45???years: a proposed method, Alimentary Pharmacology & Therapeutics, vol.95, issue.Suppl 1, pp.1078-1086, 2009.
DOI : 10.1111/j.1572-0241.2002.05786.x

G. Fiorino, S. Danese, and B. Pariente, Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-?? agents, Autoimmunity Reviews, vol.13, issue.1, pp.15-24, 2014.
DOI : 10.1016/j.autrev.2013.06.005

H. Thiebault, P. Boyard-lasselin, and C. Guignant, Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab, European Journal of Gastroenterology & Hepatology, vol.28, issue.8, p.36, 2017.
DOI : 10.1097/MEG.0000000000000643

G. Klingenstein, R. Levy, and A. Kornbluth, Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature, Alimentary Pharmacology and Therapeutics, vol.77, issue.3, pp.243-249, 2005.
DOI : 10.1097/00003086-199603000-00020

H. Yanai, D. Shuster, and E. Calabrese, The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies, Inflammatory Bowel Diseases, vol.86, issue.13, pp.2778-86, 2013.
DOI : 10.1097/MD.0b013e3181441a68

K. Forrest, D. Symmons, and P. Foster, Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease?, Alimentary Pharmacology and Therapeutics, vol.125, issue.10, pp.1035-1078, 2004.
DOI : 10.1046/j.1365-2036.2003.01596.x

K. Takeuchi, S. Smale, and P. Premchand, Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug???Induced Clinical Relapse in Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.196-202, 2006.
DOI : 10.1016/S1542-3565(05)00980-8

Y. Miedany, . El, S. Youssef, and I. Ahmed, The Gastrointestinal Safety and Effect on Disease Activity of Etoricoxib, a Selective Cox-2 Inhibitor in Inflammatory Bowel Diseases, The American Journal of Gastroenterology, vol.4, issue.4, pp.311-318, 2006.
DOI : 10.1056/NEJMoa021907

W. Sandborn, W. Stenson, and J. Brynskov, Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.203-214, 2006.
DOI : 10.1016/j.cgh.2005.12.002

G. Bonner, A. Fakhri, and S. Vennamaneni, A Long-term Cohort Study of Nonsteroidal Anti-inflammatory Drug Use and Disease Activity in Outpatients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.120, issue.6, pp.751-758, 2004.
DOI : 10.1097/00005792-197609000-00004

D. Barthel, G. Ganser, and R. Kuester, Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics, The Journal of Rheumatology, vol.42, issue.11, pp.2160-2165, 2015.
DOI : 10.3899/jrheum.140472

A. Bieber, A. Fawaz, and I. Novofastovski, Antitumor Necrosis Factor-? Therapy Downloaded by, p.36, 2017.